All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The new centre brings advanced corneal procedures pioneered in India
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
Subscribe To Our Newsletter & Stay Updated